Invion Ltd (IVX)

Sydney
0.009
-0.001(-10.00%)
  • Volume:
    1,312,777
  • Bid/Ask
    0.009/0.01
  • Day's Range
    0.009 - 0.01

IVX Overview

Prev. Close
0.009
Day's Range
0.009 - 0.01
Revenue
3.47M
Open
0.01
52 wk Range
0.006 - 0.013
EPS
0
Volume
1,312,777
Market Cap
49.84M
Dividend (Yield)
N/A (N/A)
Average Volume (3m)
1,410,888
P/E Ratio
N/A
Beta
0.52
1-Year Change
0%
Shares Outstanding
5,537,792,295
Next Earnings Date
29 Nov 2
What is your sentiment on Invion Ltd?
or
Market is currently closed. Voting is open during market hours.

Invion Ltd News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsSellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Invion Ltd Company Profile

Invion Ltd Company Profile

Employees
8
Market
Australia

Invion Limited is a clinical-stage life sciences (drug development) company. The Company is engaged in the completion of clinical development programs and targeted business development programs associated with its approximately three drug assets, such as INV102 (nadolol), INV103 (ala-Cpn10) and INV104 (zafirlukast). It focuses on the development of treatments for opportunities in chronic inflammatory and respiratory disease. INV102 (nadolol) is a beta adrenergic biased ligand targeted to treat chronic inflammatory airway diseases via the reversal of mucous metaplasia in the airway epithelium. INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein, which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesized to maintain and restore immune homeostasis.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.